Haberler


Menarini Türkiye'den haberleri görmek için sosyal medya adreslerimize tıklayınız.

 

icone_facebook    icone_instagram    icone_twitter    icone_linkedin

icona_youtube

 

 

Menarini’den Haberler

 

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma...

NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor

box_menarini_1_TR

.

box_menarini_2_TR

box_menarini_3_TR

MENARINI Group

Menarini Group hakkında daha fazla bilgi almak için...

ARAŞTIRMA & GELİŞTİRME

Menarini Group’un Araştırma&Geliştirme faaliyetlerini görmek için...

DÜNYADA MENARINI

Menarini Group’un diğer ülkelerdeki faaliyetlerini görmek için.
Scroll Top